-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s VCN-01
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's VCN-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Vanglusagene ensiparvovec
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Vanglusagene ensiparvovec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VCN-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VCN-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VCN-01 in Pancreatic Ductal Adenocarcinoma Drug Details: VCN-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Retatrutide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Retatrutide in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retatrutide in Type 2 Diabetes Drug Details: Retatrutide (LY-3437943) is...
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s Ribaxamase
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's Ribaxamase report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s SYN-020
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's SYN-020 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8543 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8543 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8543 in Chronic Lymphocytic Leukemia (CLL) Drug Details: JNJ-80948543 is...
-
Product Insights
NewInfectious Diarrhea – Drugs In Development, 2024
Empower your strategies with our Infectious Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions. Infectious Diarrhea is a common gastrointestinal infection and the most common type of diarrhea. Diarrhea is defined as frequent bowel movements that are loose, watery, and associated with nausea, vomiting, and fatigue. Bacterial, viral, and protozoans are the common pathogens leading to infectious diarrhea. E. coli-associated infections are the most common bacteria while Entamoeba histolytica is a common parasite causing infectious diarrhea....
-
Product Insights
NewEnteritis – Drugs In Development, 2024
Empower your strategies with our Enteritis – Drugs In Development, 2024 report and make more profitable business decisions. Enteritis is an inflammation of the intestines. It could be either infectious and non-infectious caused by bacteria, viral and protozoans. Secondary infections are caused by radiation, excess alcohol, drug toxicity. Mode of infection is air borne, inhalational, contaminated food, water. Etiology includes primarily pathogens and food poisoning too. Symptoms are primarily diarrhea, dehydration, weight loss, abdominal pain. Diagnosis is through physical examination and...